1. Home
  2. OABI vs MGTX Comparison

OABI vs MGTX Comparison

Compare OABI & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OmniAb Inc.

OABI

OmniAb Inc.

N/A

Current Price

$4.66

Market Cap

773.1M

Sector

Health Care

ML Signal

N/A

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

N/A

Current Price

$8.00

Market Cap

881.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OABI
MGTX
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
773.1M
881.7M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
OABI
MGTX
Price
$4.66
$8.00
Analyst Decision
Strong Buy
Buy
Analyst Count
7
8
Target Price
$8.33
★ $27.75
AVG Volume (30 Days)
★ 1.3M
563.9K
Earning Date
10-30-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
6.56
★ 33.02
EPS
N/A
★ 0.68
Revenue
$18,666,000.00
★ $81,391,000.00
Revenue This Year
$94.10
$309.55
Revenue Next Year
$30.33
N/A
P/E Ratio
★ N/A
$11.98
Revenue Growth
N/A
★ 144.57
52 Week Low
$1.35
$6.62
52 Week High
$5.45
$15.35

Technical Indicators

Market Signals
Indicator
OABI
MGTX
Relative Strength Index (RSI) 42.52 33.45
Support Level $4.53 $6.93
Resistance Level $5.43 $10.08
Average True Range (ATR) 0.32 0.53
MACD -0.05 -0.06
Stochastic Oscillator 4.76 7.34

Price Performance

Historical Comparison
OABI
MGTX

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: